News | June 15, 2012

Naviscan PEM Research Presented At SNM 2012

Studies focused on novel radiotracers, new applications and clinical validation of low-dose positron emission mammography

June 15, 2012 — Several groundbreaking studies on the Naviscan PET scanner, the breast application for which is positron emission mammography (PEM), were presented this week at the annual meeting of the Society of Nuclear Medicine (SNM) in Miami, Fla. Researchers from the Johns Hopkins University, Thomas Jefferson University, Boston University and University of Washington presented abstracts focusing on use of novel radiotracers, new clinical applications as well as low-dose imaging with PEM. 

Mathew Thakur, M.D., from Thomas Jefferson University presented results of an ongoing head-to-head comparison of 18F-FDG with a novel low-dose radiotracer Cu-64-TP3805 (NuView Life Sciences, Park City, UT) demonstrating concordance. This is significant since the dose from Cu-64 is similar to one mammogram and does not require fasting indicating a potential for PEM to be used in a screening capacity. Richard Wahl, M.D. of Johns Hopkins University presented results on feasibility of using the technology for metabolic assessment and evaluation of treatment response for patients with osteoarthritis. Gustavo Mercier, M.D. from Boston University and Lawrence MacDonald from University of Washington shared clinical and research validations of performing PEM imaging using 50 percent less radiation. 

PEM imaging shows the location as well as the metabolic phase of a lesion. This information is critical in determining whether a lesion is malignant and influences the course of treatment by providing an ability to distinguish between benign and malignant lesions, what researchers term “specificity.” Recent studies have demonstrated that PEM has similar sensitivity and higher specificity than breast MRI. The scanner is the only U.S. Food and Drug Administration-cleared, CE-certified 3D molecular breast imaging (MBI), device on the market with biopsy-guidance. 

For more information: 

Related Content

Fujifilm Debuts Aspire Bellus II, A New Multimodality Mammography Workstation
News | Mammography | March 08, 2018
March 8, 2018 –   Fujifilm Medical Systems U.S.A. Inc., a provider of diagnostic imaging products with a comprehensiv
Breast cancer screening guidelines may lead to delayed diagnosis in nonwhite women
News | Oncology Diagnostics | March 08, 2018
March 8, 2018 – The current guidelines for mammographic...
Imaging agent helps predict success of lung cancer therapy
News | Oncology Diagnostics | March 08, 2018
March 8, 2018 – Doctors contemplating the best therapy for...
Four compelling reasons to begin annual mammograms at 40
News | Mammography | March 07, 2018
Turning 40 is a benchmark birthday for many women in the United States.
Another benefit of tomosynthesis is reducing patients’ radiation exposure, which is especially important if they need additional testing.

Another benefit of tomosynthesis is reducing patients’ radiation exposure, which is especially important if they need additional testing.

Feature | Women's Health | March 06, 2018 | By Katherine Hall, M.D.
Technological advances — particularly the adoption of 3-D digital breast tomosynthesis (DBT) — are making it possible...
Katherine Hall, M.D.

Katherine Hall, M.D.

Sponsored Content | Case Study | Mammography | March 06, 2018
Located in a spacious 25,000-square-foot facility on the Presbyterian Hospital of Dallas campus, Southwest Diagnostic...
News | Women's Health | March 02, 2018
Philips and Hologic, Inc. announced a global partnership agreement to offer care professionals integrated solutions...
Fujifilm Announces Nine Additional U.S. Installations of Aspire Cristalle With 3-D Mammography
News | Mammography | February 28, 2018
Fujifilm Medical Systems U.S.A. Inc. announced nine of the initial healthcare systems across the United States that...
Sponsored Content | Videos | Women's Health | February 27, 2018
Fujifilm details its latest innovations in women's health including its ASPIRE Cristalle mammography system with...
Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...
Overlay Init